Drugs /

romidepsin

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
romidepsin
Trade Name(s):
Istodax
NCI Definition [1]:
A bicyclic depsipeptide antibiotic isolated from the bacterium Chromobacterium violaceum with antineoplastic activity. After intracellular activation, romidepsin binds to and inhibits histone deacetylase (HDAC), resulting in alterations in gene expression and the induction of cell differentiation, cell cycle arrest, and apoptosis. This agent also inhibits hypoxia-induced angiogenesis and depletes several heat shock protein 90 (Hsp90)-dependent oncoproteins.

Clinical Trials

View Clinical Trials for romidepsin

Romidepsin has been investigated in 18 clinical trials, of which 15 are open and 3 are closed. Of the trials investigating romidepsin, 6 are phase 1 (5 open), 8 are phase 1/phase 2 (6 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).

HER2 Deficient Expression, HER2 Negative, and BCL6 Expression are the most frequent biomarker inclusion criteria for romidepsin clinical trials.

Peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma are the most common diseases being investigated in romidepsin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Romidepsin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Romidepsin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating romidepsin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
depsipeptide, antibiotic fr 901228, Istodax, fk228
Drug Categories [2]:
Histone deactylase/HDAC inhibitors
Drug Target(s) [2]:
HDAC1, HDAC2, HDAC3, HDAC8
NCIT ID [1]:
C1544

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.